Chiasma, Inc.   Report issue

For profit Phase 3
Founded: Jerusalem Israel (2001)
Status: Acquired by Amryt Research Limited (2021) → now Chiesi (2023)

Organization Overview

First Clinical Trial
2012
NCT01412424
First Marketed Drug
2020
octreotide (sandostatin)
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

CHIASMA | Chiasma, Inc.

Active Ingredients

Marketed Drugs (1)

octreotide (sandostatin) (2020)

Drugs in Phase 3 Trials (3)

cabergoline (dostinex) (1 trial)

lanreotide (somatuline depot) (1 trial)

octreotide (sandostatin) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acromegaly (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 3